Literature DB >> 16026300

Pharmacological management of acutely agitated schizophrenic patients.

L San1, B Arranz, R Escobar.   

Abstract

Agitation is commonly seen in acute schizophrenic patients and core symptoms include a wide range of symptom. It requires rapid and effective treatment approaches in order to protect patient and caregiver from potential injury. Clinician's decision of pharmacological treatment should be individualized to the needs and circumstances of the patient. Benzodiazepines, typical antipsychotics, and combinations of typical antipsychotics and benzodiazepines have been widely used as treatment options. Atypical antipsychotics have clear advantages over the typical drugs as they generally show a much better safety and tolerability profile, particularly to EPS and related side effects, however clinical perception regarding efficacy in treating acutely agitated psychotic patient is controversial. New intramuscular atypical antipsychotic formulations offer evidence of being at least as effective as typical antipsychotics in controlling agitation. Therefore, they should be considered as first line therapy in agitated schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026300     DOI: 10.2174/1381612054367472

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Two Sudden and Unexpected Deaths of Patients with Schizophrenia Associated with Intramuscular Injections of Antipsychotics and Practice Guidelines to Limit the Use of High Doses of Intramuscular Antipsychotics.

Authors:  Nasratullah Wahidi; Katie M Johnson; Allen Brenzel; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2016-08-15

2.  Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study.

Authors:  Su-Zhen Zhang; Yong-Gang Mu; Qi Liu; Ying Shi; Li-Hua Guo; Ling-Zhi Li; Fu-De Yang; Yong Wang; Tao Li; Qi-Yi Mei; Hong-Bo He; Zhi-Yu Chen; Zhong-Hua Su; Tie-Bang Liu; Shi-Ping Xie; Qing-Rong Tan; Jin-Bei Zhang; Cong-Pei Zhang; Hong Sang; Wei-Feng Mi; Hong-Yan Zhang
Journal:  BMC Psychiatry       Date:  2019-07-10       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.